E-Mail
Leveraging on Asian patient data, the 5-year collaboration aims to boost patientcentricity in R&D, leading to improved treatment outcomes in cardiovascular disease (CVD) management.
The Center will generate and integrate high quality patient data into early clinical research to inform future targeted therapies for CVDs.
Bayer will contribute S$5.4million (approx. EUR 3.4 million) towards this
collaboration.
Singapore, December 17, 2020 - Bayer and National Heart Centre Singapore (NHCS) today announced that they have entered into a 5-year collaboration agreement to set up Center of Excellence for Explorative Cardiovascular Studies (hereinafter Center ) with the aim of boosting patient-centricity in research and development (R&D) and improving treatment outcomes in cardiovascular disease (CVD) management. Combining NHCS vast